104 results
Search Results
2. Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients.
3. Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection.
4. Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply.
5. Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply.
6. Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight.
7. Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply.
8. Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B.
9. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data.
10. Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
11. Editorial: Time to consider early treatment for chronic hepatitis B in both children and adults.
12. Letter: Consensus in international guidelines when discontinuing nucleos(t)ide analogue therapy in patients with chronic hepatitis B.
13. Editorial: Time to consider early treatment for chronic hepatitis B in both children and adults—authors' reply.
14. Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection—Authors' reply.
15. Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection.
16. Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments.
17. Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments—Authors' reply.
18. Editorial: risk of renal function decline in patients with chronic hepatitis B virus infection treated with nucleos(t)ide analogues.
19. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies.
20. Formation of semi‐enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant.
21. Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
22. Editorial: baseline hepatitis B virus haplotype number may help predict a functional cure in patients with chronic hepatitis B treated with nucleotide analogues—authors' reply.
23. Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients—authorsʼ reply.
24. Letter: improved alanine aminotransferase level in non‐cirrhotic and low‐viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues —authorsʼ reply.
25. Letter: improved alanine aminotransferase level in patients with chronic hepatitis B without cirrhosis and low viral load treated with nucleotide/nucleoside analogues.
26. Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients.
27. Editorial: baseline hepatitis B virus haplotype number may help predict a functional cure in patients with chronic hepatitis B treated with nucleotide analogues.
28. Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease.
29. Letter: serum HBV RNA and HBcrAg may help to evaluate safely stopping nucleot(s)ide analogues in patients with HBeAg‐negative chronic hepatitis B and without cirrhosis.
30. Editorial: tripartite motif 26 inhibits hepatitis B virus replication and its genetic polymorphism predicts response to interferon treatment—towards a better understanding of interferon responsiveness in chronic hepatitis B.
31. Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B ‐ author's reply.
32. Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B.
33. Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients—author's reply.
34. Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B.
35. Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection—Authors' reply.
36. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
37. Editorial: is functional cure the only holy grail for treatment discontinuation in patients with HBeAg‐negative chronic hepatitis B?
38. Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease—time to get some skin in the game. Authors' reply.
39. Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease—time to get some skin in the game.
40. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.
41. Letter: systematic review with meta‐analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B—authors' reply.
42. Letter: systematic review with meta‐analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B.
43. Letter: hepatic steatosis and fibrosis in chronic hepatitis B—the chicken‐and‐egg conundrum. Authors' reply.
44. Letter: hepatic steatosis in chronic hepatitis B—viral, metabolic or treatment‐related?
45. Letter: hepatic steatosis and fibrosis in chronic hepatitis B—the chicken‐and‐egg conundrum.
46. Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti‐viral therapy—authors' reply.
47. Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti‐viral therapy.
48. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B‐related compensated cirrhosis—authors' reply.
49. Letter: tenofovir may be superior to entecavir for treatment‐naïve chronic hepatitis B patients.
50. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B‐related compensated cirrhosis.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.